tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RLYB Stock Latest News

Rallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition
Company AnnouncementsRallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition
8d ago
RLYB
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
PremiumMarket News
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
24d ago
RLYB
RXRX
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
24d ago
B
APP
Rallybio Sells REV102 Program to Recursion Pharmaceuticals
PremiumCompany Announcements
Rallybio Sells REV102 Program to Recursion Pharmaceuticals
25d ago
8K
RLYB
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
PremiumThe Fly
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
25d ago
RLYB
RXRX
Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102
PremiumThe FlyRecursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102
25d ago
RLYB
RXRX
Rallybio Finalizes Employment Agreement with CMO
Premium
Company Announcements
Rallybio Finalizes Employment Agreement with CMO
1M ago
8K
RLYB
Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization
Premium
Company Announcements
Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization
1M ago
RLYB
Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk
PremiumCompany Announcements
Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk
1M ago
RLYB
Rallybio initiates dosing in RLYB116 study
PremiumThe Fly
Rallybio initiates dosing in RLYB116 study
2M ago
RLYB
Rallybio Elects New Directors at Shareholder Meeting
PremiumCompany Announcements
Rallybio Elects New Directors at Shareholder Meeting
3M ago
8K
RLYB
Rallybio Reports Q1 2025 Financial Results and Strategic Updates
PremiumCompany Announcements
Rallybio Reports Q1 2025 Financial Results and Strategic Updates
3M ago
RLYB
Rallybio reports Q1 EPS (21c), consensus (28c)
PremiumThe FlyRallybio reports Q1 EPS (21c), consensus (28c)
3M ago
RLYB
Rallybio downgraded to Hold from Buy at JonesResearch
Premium
The Fly
Rallybio downgraded to Hold from Buy at JonesResearch
4M ago
RLYB
Rallybio downgraded to In Line from Outperform at Evercore ISI
Premium
The Fly
Rallybio downgraded to In Line from Outperform at Evercore ISI
4M ago
RLYB
Rallybio downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Rallybio downgraded to Neutral from Buy at H.C. Wainwright
4M ago
RLYB
Citizens JMP downgrades Rallybio on RLYB212 discontinuation
PremiumThe Fly
Citizens JMP downgrades Rallybio on RLYB212 discontinuation
4M ago
RLYB
Rallybio downgraded to Market Perform from Outperform at Citizens JMP
PremiumThe Fly
Rallybio downgraded to Market Perform from Outperform at Citizens JMP
4M ago
RLYB
Rallybio discontinues RLYB212 program
PremiumThe Fly
Rallybio discontinues RLYB212 program
4M ago
RLYB
Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
PremiumRatingsRallybio’s Promising Developments and Financial Stability Justify Buy Rating
5M ago
RLYB
Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
Premium
Ratings
Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
5M ago
RLYB
Rallybio Corporation Reports 2024 Financial Results and Progress
Premium
Company Announcements
Rallybio Corporation Reports 2024 Financial Results and Progress
5M ago
RLYB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >